We describe the case of a 51-year-old woman with HCV-associated cryoglobulinemic glomerulonephritis (GN). She presented mild deterioration of kidney function, non-nephrotic proteinuria, and active urinary sediment. Kidney biopsy showed features of membranoproliferative changes with some sclerosis. Sustained viral response (SVR) was obtained by 6 months of antiviral therapy (peg-IFN-α2a plus ribavirin). SVR was linked with improvement of kidney function and remission of proteinuria. Clinical and virological remission persists over a 25-month follow-up. This case report emphasizes efficacy and safety of antiviral treatment of HCV-associated glomerulonephritis – preliminary but encouraging results exist. We identified by systematic review of the literature 9 studies (156 unique patients); the pooled estimate of frequency of sustained virological response after IFN-based therapy was 0.49 (95% confidence interval, CI: 0.21, 0.77; p < 0.0005; random effects model). Heterogeneity was found (I2 = 98.9%, p < 0.0001). Two possible regimens should be considered for the treatment of HCV-associated cryoglobulinemic GN according to the clinical presentation. Immunosuppressive therapy is recommended for HCV-related kidney disease having aggressive course, and recent evidence supports rituximab (RTX) use with a reduced exposure to corticosteroids. We identified six studies (66 unique patients) on RTX therapy for HCV-associated kidney disease; at the end of RTX therapy, the pooled estimate of the mean decrease in proteinuria was 1.4 g/24 h (95% CI: 0.75, 2.05, p < 0.001); The p test for heterogeneity gave a value of 0.94 (I2 = 0). Several questions related to RTX use remain. HCV-induced GN is uncommon among CKD patients of developed countries, and this clearly hampers prospective controlled clinical trials aimed to evaluate efficacy and safety of antiviral or immunosuppressive therapy in this population.

Keywords:
Interferon, Rituximab, Glomerulonephritis, Cryoglobulinemia, Hepatitis C
1.
Lauer G, Walker B: Hepatitis C virus infection. N Engl J Med 2001;345:41–52.
2.
Pascual M, Perrin L, Giostra E, Schifer J: Hepatitis C virus in patients with cryoglobulinemia type II. J Infect Dis 1990;162:567–569.
3.
Ferri C, Greco F, Longombardo G, Palla P, Moretti A, Marzo E, Foselle P, Pasero G, Bombardieri S: Antibodies to hepatitis C virus in patients with mixed cryoglobulinemia. Arthritis Rheum 1991;34:1606–1610.
4.
Agnello V, Chung R, Kaplan L: A role of hepatitis C infection in type II cryoglobulinemia. N Engl J Med 1992;327:1490–1495.
5.
Fabrizi F, Colucci P, Ponticelli C, Locatelli F: Kidney and liver involvement in cryoglobulinemia. Semin Nephrol 2002;22:309–318.
6.
Johnson R, Willson R, Yamabe H, Couser W, Alpers C, Wener M, Davis C, Gretch D: Renal manifestations of hepatitis C virus infection. Kidney Int 1994;46:1255–1263.
7.
D’Amico G: Renal involvement in hepatitis C infection: cryoglobulinemic glomerulonephritis. Kidney Int 1998;54:650–671.
8.
Kasuno K, Ono T, Matsumori A, Nogaki F, Kusano H, Watanabe H, Yodoi J, Muso E: Hepatitis C virus associated tubulo-interstitial injury. Am J Kidney Dis 2003;41:767–775.
9.
Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int 2008;73(suppl 109):S1–S99.
10.
Roccatello D, Baldovino S, Rossi D, Mansouri M, Naretto C, Gennaro M, Cavallo R, Alper M, Costanzo P, Giachino O, Mazzucco G, Sena L: Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant 2004;19:3054–3061.
11.
Garini G, Allegri L, Carnevali L, et al: Interferon alfa in combination with ribavirin as initial treatment for hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis. Am J Kidney Dis 2001;38:E35–E39.
12.
Johnson R, Gretch D, Couser W, Alpers C, Willson J, Chung M, Hart J, Willson R: Hepatitis C virus-associated glomerulonephritis. Effect of alpha-interferon therapy. Kidney Int 1994;46:1700–1704.
13.
Stehman-Breen C, Alpers C, Couser W, Willson R, Johnson R: Hepatitis C virus associated membranous glomerulonephritis. Clin Nephrol 1995;44:141–147.
14.
Fabrizi F, Pozzi C, Farina M, Dattolo P, Lunghi G, Badalamenti S, Pagano A, Locatelli F: Hepatitis C virus infection and acute or chronic glomerulonephritis: an epidemiological and clinical appraisal. Nephrol Dial Transplant 1998;13:1991–1997.
15.
Komatsuda A, Imai H, Wakui H, Hamai K, Ohtani H, Kodama T, Oyama Y, Nakamoto Y: Clinicopathological analysis and therapy in hepatitis C virus-associated nephropathy. Intern Med 1996;35:529–533.
16.
Al-Wakeel J, Mitwalli A, Tarif N, Al-Mohaya S, Malik G, Khalil M: Role of interferon-alpha in the treatment of primary glomerulonephritis. Am J Kidney Dis 1999;33:1142–1146.
17.
Beddhu S, Bastacky S, Johnson J: The clinical and morphologic spectrum of renal cryoglobulinemia. Medicine (Baltimore) 2002;81:398–409.
18.
Colucci G, Manno C, Grandaliano G, Schena FP: Cryoglobulinemic membrano-proliferative glomerulonephritis: beyond conventional therapy. Clin Nephrol 2011;75:374–379.
19.
Mazzaro C, Panarello G, Carniello S, Faelli A, Mazzi G, Crovatto M, Baracetti S, Nascimbeni F, Zorat F, Pozzato G, Faccini L, Campanacci L: Interferon versus steroids in patients with hepatitis C virus-associated glomerulonephritis. Digest Liver Dis 2000;32:708–715.
20.
Bruchfeld A, Lindahl K, Stahle L, Soderberg M, Schvarcz R: Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. Nephrol Dial Transplant 2003;18:1573–1580.
21.
Rossi P, Bertani T, Baio P, Caldara R, Luliri P, Tengattini F, Bellavita P, Mazzucco G, Misiani R: Hepatitis C virus-related cryoglobulinemic glomerulonephritis: long-term remission after antiviral therapy. Kidney Int 2003;63:2236–2241.
22.
Alric L, Plaisier E, Thébault S, Péron JM, Rostaing L, Pourrat J, Ronco P, Piette JC, Cacoub P: Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN. Am J Kidney Dis 2004;43:617–623.
23.
Saadoun D, Resche-Rigon M, Thibault V, Piette J, Cacoub P: Antiviral therapy for hepatitis C-associated mixed cryoglobulinemia vasculitis. Arthritis Rheum 2006;54:3696–3706.
24.
Garini G, Allegri L, Iannuzzella F, Vaglio A, Buzio C: HCV-related cryoglobulinemic glomerulonephritis: implications of antiviral and immunosuppressive terapies. Acta Biomed 2007;78:51–59.
25.
Roccatello D, Fornasieri A, Giachino O, Rossi D, Beltrame A, Banfi G, Confalonieri R, Tarantino A, Pasquali S, Amoroso A, Savoldi S, Colombo V, Manno C, Ponzetto A, Moriconi L, Pani A, Rustichelli R, Barbiano di Belgiojoso G, Comotti C, Quarenghi M: Multicenter study on hepatitis C virus-related cryoglobulinemic glomerulonephritis. Am J Kidney Dis 2007;49:69–82.
26.
Abbas G, Hussain S, Shafi T: Effect of antiviral therapy on hepatitis C virus related glomerulopathy. Saudi J Kidney Dis Transplant 2008;19:775–780.
27.
Saadoun D, Resche Rigon M, Sene D, Terrier B, Karras A, Perard L, Schoindre Y, Coppéré B, Blanc F, Musset L, Piette JC, Rosenzwajg M, Cacoub P: Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood 2010;116:326–334.
28.
Quartuccio L, Soardo G, Romano G, Zaja F, Scott C, De Marchi G, Fabris M, Ferraccioli G, De Vita S: Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinemia: efficacy and safety in the absence of steroids. Rheumatology 2006;45:842–846.
29.
Petrarca A, Rigacci L, Monti M, Giannini C, Bernardi F, Caini P, Colagrande S, Bosi A, Laffi G, Zignego AL: Improvement in liver cirrhosis after treatment of HCV-related mixed cryoglobulinemia with rituximab. Dig Liver Dis 2007;39(suppl 1):S129–S133.
30.
Roccatello D, Baldovino S, Rossi D, Giachino O, Mansouri M, Naretto C, Di Simone D, Francica S, Cavallo R, Alpa M, Napoli F, Sena L: Rituximab as a therapeutic tool in severe mixed cryoglobulinemia. Clin Rev Allergy Immunol 2008;34:111–117.
31.
Saadoun D, Mesche-Rigon M, Sene D, Perard L, Karras A, Cacoub P: Rituximab combined with peg-interferon-ribavirin refractory hepatitis C virus-associated cryoglobulinemia vasculitis. Ann Rheum Dis 2008;67:1431–1436.
32.
Ferri C, Cacoub P, Mazzaro C, Roccatello D, Scaini P, Sebastiani M, Tavoni A, Zignego AL, De Vita S: Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature. Autoimmun Rev 2011;11:48–55.
33.
De Vita S, Quartuccio L, Isola M, Mazzaro C, Scaini P, Lenzi M, Campanini M, Naclerio C, Tavoni A, Pietrogrande M, Ferri C, Mascia M, Masolini P, Zabotti A, Maset M, Roccatello D, Zignego A, Pioltelli P, Gabrieli A, Filippini D, Perrella O, Migliaresi S, Galli M, Bombardieri S, Monti G: A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum 2012;64:843–853.
34.
Ahmed M, Wong C: Should rituximab be the rescue therapy for refractory mixed cryoglobulinemia associated with hepatitis C? J Nephrol 2007;20:350–356.
35.
Cacoub P, Delluc A, Saadoun D, Landau DA, Sene D: Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand? Ann Rheum Dis 2008;67:283–287.
36.
El-Serag H, Hampel H, Yeh C, Rabaneck L: Extra-hepatic manifestations of hepatitis C among United States male veterans. Hepatology 2002;36:1439–1445.
37.
Perico N, Cattaneo D, Bibkov B, Remuzzi G: Hepatitis C infection and chronic renal diseases. Clin J Am Soc Nephrol 2009;4:207–220.
38.
Sneller M, Hu Z, Langford C: A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum 2012;64:835–842.
39.
Basse G, Ribes D, Kamar N, Mehrenberger M, Sallusto F, Esposito L, Guitard J, Lavayssiere L, Oksman F, Durand D, Rostaing L: Rituximab therapy for mixed cryoglobulinemia in seven renal transplant patients. Transplant Proc 2006;38:2308–2310.
40.
Fabrizi F, Martin P, Elli A, Montagnino G, Banfi G, Passerini P, Campise R, Tarantino A, Ponticelli C: Hepatitis C virus infection and rituximab therapy after renal transplantation. Int J Artif Organs 2007;30:445–449.
41.
McHutchison JG, Everson GT, Gordon SC, Jacobson I, Sulkowski M, Kauffman R, McNair L, Alam J, Muir A, PROVE1 Study Team: Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009;360:1827–1838.
42.
Hezode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, Browicki J, Bourliere M, Gharakhanian S, Bengtsson L, McNair L, George S, Kieffer T, Kwong A, Kauffman R, Alam J, Pawlotsky J, Zeuzem S, PROVE2 Study Team: Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009;360:1839–1850.
43.
Ghany G, Nelson D, Strader D, Thomas D, Seeff L: An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guidelines by the American Association for the Study of Liver Diseases. Hepatology 2011;54:1433–1434.
44.
Saadoun D, Rosenzwajg M, Joly F, Six A, Carrat F, Thibault V, Sene D, Cacoub P, Klatzmann D: Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med 2011;365:2067–2077.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.